AGENUS INC (AGEN)
Health Care · biotechnology · NASDAQ
Agenus is a biotechnology company advancing a novel, multifunctional immunotherapy combination for difficult-to-treat cancers like MSS colorectal cancer.
What AGENUS INC does
Agenus is a clinical-stage biotechnology company focused on discovering and developing immuno-oncology therapies for cancer. Its primary pipeline centers on the development of botensilimab (an Fc-enhanced anti-CTLA-4 antibody) and balstilimab (an anti-PD-1 antibody) for the treatment of various cancers, including microsatellite-stable (MSS) colorectal cancer. The company also generates revenue through its QS-21 STIMULON vaccine adjuvant business and equity interests in other biotechnology ventures.
Recent developments
Agenus initiated the strategic prioritization of its BOT/BAL combination for the neoadjuvant treatment of MSS colon cancer, supported by the planned Phase 3 ROBBIN trial expected to initiate in Q1 2027. The company recently completed a private placement providing $85 million in upfront gross proceeds to support this clinical program and secured the dismissal of related securities litigation.
From AGENUS INC's filing of 2026-08-07.
Themes: immuno-oncology, cancer therapy, clinical trials, neoadjuvant treatment, vaccine adjuvants
Fundamentals
- Price$6.42 as of 2026-10-20 close
- Market cap$289M as of 2026-08-04 (share count; price 2026-10-20)
- 1-year return+45.2% 2025-10-20 close $4.42 → 2026-10-20 close $6.42
- P/E2.15 as of 2026-10-20
- Net margin-2.7% FY2025, SEC XBRL
- ROICn/a No figure: its pre-tax income was zero or negative, so there is no tax rate to apply.
- Debt / equityn/a No figure: its interest expense implies more borrowing than the debt lines we read add up to.
- Revenue growth (YoY)+10.4% FY2025, SEC XBRL
- Revenue CAGR (3y)+5.2% SEC XBRL
- Beta1.56 as of 2026-09-03
- Last reported earnings2026-08-06 SEC EDGAR Form 8-K (Item 2.02)
How AGEN compares in its sector
- price-to-earnings ratiobottom 10% 181 covered Health Care peers, as of 2026-10-20
- net profit marginmiddle range 430 covered Health Care peers, as of 2026-09-03
- operating marginmiddle range 417 covered Health Care peers, as of 2026-09-03
- 3-year revenue CAGRmiddle range 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)middle range 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Quarterly results
| Quarter | Revenue | Operating income | Net income | Diluted EPS | Operating cash flow | Capex |
|---|---|---|---|---|---|---|
| Q2 FY2026 2026-06-30 | $35M | $11M | -$567000 | -$0.01 | -$31M† | $0† |
| Q1 FY2026 2026-03-31 | $34M | $15M | $39M | $1.02 | -$36M | $0 |
| Q4 FY2025 2025-12-31 | $34M† | $14M† | -$11M† | -$0.37† | -$17M† | $0† |
| Q3 FY2025 2025-09-30 | $30M | -$5M | $64M | $1.94 | -$15M† | $0† |
| Q2 FY2025 2025-06-30 | $26M | -$17M | -$30M | -$1.00 | -$20M† | $1000† |
| Q1 FY2025 2025-03-31 | $24M | -$13M | -$26M | -$1.03 | -$26M | $5000 |
| Q4 FY2024 2024-12-31 | $27M† | -$26M† | -$47M† | -$1.94† | -$29M† | $73000† |
| Q3 FY2024 2024-09-30 | $25M | -$32M | -$67M | -$3.08 | -$53M† | $7000† |
† Not filed as a discrete quarter: derived from the company's own year-to-date figures (for example the fourth quarter as the fiscal year minus the first nine months). A derived per-share figure is approximate, because the share count moves within the year.
Balance sheet at 2026-06-30
- Cash and equivalents$19M
- Total debtnot shown the filing tags none of the debt lines we read — not evidence of zero debt
From the company's own SEC 10-Q and 10-K filings (XBRL), re-read every week. Figures in US dollars as filed; informational only — not financial advice.
How AGENUS INC looks technically
AGENUS INC (AGEN) is trading 33.1% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 61 trading days ago — a "golden cross", a bullish long-term signal. A trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 23 (a reading of 25+ marks a strong trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 39, neither overbought (above 70) nor oversold (below 30). It made a new 20-day low about 3 trading days ago. It is 37.7% below its highest point of the past year.
Trend
8
| Distance from the 200-day | it is trading 33.1% above its 200-day average, the long-term trend line — a longer-term uptrend | +33.1% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $7.70 | $7.70 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $4.82 | $4.82 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing high 20 calendar days ago — the swings before that are what the structure reading is measured on | 20 sessions |
| Wave structure | its recent swings can be read as a completed three-part upward correction — a pullback in the A-B-C shape Elliott-wave chartists use; the labelling fails if price closes above 10.31. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible three-wave upward correction, complete (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 61 trading days ago — a "golden cross", a bullish long-term signal | 61 sessions |
| Trend strength (14-day ADX) | a trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 23 (a reading of 25+ marks a strong trend) | 22.8 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 39, neither overbought (above 70) nor oversold (below 30) | 38.9 |
|---|---|---|
| Position in its 14-day range | it is trading near the bottom of its 14-day range ($6.00 to $9.99) — its "stochastic" reading is 11 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 10.5 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in negative territory (momentum leaning bearish) | 11 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $10.31 | $10.31 |
|---|---|---|
| From the 52-week high | it is 37.7% below its 52-week high (its highest price of the past year) | -37.7% |
| Above the 52-week low | it is 136.9% above its 52-week low (its lowest price of the past year) | +136.9% |
| Below the 52-week high | it is 37.7% below its highest point of the past year | 37.7% |
| Since a 20-day breakout | it made a new 20-day low about 3 trading days ago | 3 sessions |
| Since a 55-day breakout | it made a new 55-day low about 3 trading days ago | 3 sessions |
| All-time high | its highest closing price on record is $847.72 (set on 2006-02-17) | $847.72 |
| Given back of the 52-week move | over the past year its closes ranged ($2.77 to $9.93), and it has given back around half of its rise from last year’s low — 49% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $5.28 to $5.51. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 49.0% |
| From the all-time high | it is 99.2% below its all-time high | -99.2% |
| Nearest price level | it is trading 1.0% above a support level at $6.36 — a price it turned at twice since 2025-06-06, most recently on 2026-08-10. Since 2024-10-21 it has 11 such levels below the current price and 2 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -1.0% |
| All-time low | its lowest closing price on record is $1.38 (set on 2025-04-07) | $1.38 |
| Above the all-time low | it is 365.2% above its all-time low | +365.2% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually wide versus its own recent history (wider than about 81% of the past ~6 months) | 81st percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.5847 between its high and its low — about 9.1% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.5847 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $5.55 and $10.11 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $5.55 – $7.83 – $10.11 |
| Typical daily range (% of price) | its price moves about 9.1% in a typical session — among the most volatile in the catalog. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 9.1% |
| Stretch from the 200-day average | it is trading 2.7 daily ranges above its 200-day average price (33.1% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 2.7 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.75× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
2
| Since a doji | 8 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 8 sessions ago |
|---|---|---|
| Since a bullish engulfing | today it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | today |
Price gaps
3
| Gap at the open | it opened on 2026-10-20 1.3% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | -1.3% |
|---|---|---|
| Open gap | it gapped 4.3% above the previous close 1 session ago and has not traded back through the level it left behind at 6.04 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +4.3% |
| Gap filled | a 2.8% gap down opened on 2026-10-07 has been "filled" 9 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 9 sessions ago |
Price streaks
1
| Closing streak | it has closed higher 2 sessions in a row, a +6.29% move over the run — an unbroken run of up days, which describes what has already happened and says nothing about the next session | 2 sessions up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 19.2 percentage points (the stock lost 18.2% while the market gained 1.0%) | -19.2% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 25.5 percentage points (the stock gained 29.2% while the market gained 3.6%) | +25.5% |
| vs market, 6 months | over the past 6 months this stock beat the market by 36.7 percentage points (the stock gained 45.2% while the market gained 8.5%) | +36.7% |
| vs market, 12 months | over the past 12 months this stock beat the market by 30.7 percentage points (the stock gained 45.2% while the market gained 14.6%) | +30.7% |
Signal agreement
2
| Bullish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, outperforming the market over 6 months, near the bottom of its 14-day range (oversold) — these describe past price behaviour, not a forecast | 4 of 9 |
|---|---|---|
| Bearish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bearish state: a fresh 20-day low, MACD momentum is negative — these describe past price behaviour, not a forecast | 2 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading inside the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-14 and projected forward over today's price, the zone traders read as unresolved — neither side has established a trend, and the band is where that gets settled. The band itself is thick, spanning 24.6% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | 0.0% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 13% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $5.70 — a volume-weighted average of daily closes over 198 sessions, not a true tick-by-tick VWAP. | +12.7% |
|---|---|---|
| Vs the average paid since it last reported | the price is 17% below the average price paid since it last reported on 2026-08-06 (its 8-K), so the typical buyer over that stretch is under water. That average is $7.76 — a volume-weighted average of daily closes over 53 sessions, not a true tick-by-tick VWAP. | -17.3% |
Price levels it has turned at before
AGEN last closed at $6.42 on 2026-10-20. Since 2024-10-21 it has turned at 11 prices below its last close and 2 above; the 3 nearest below and the 2 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $6.36 | Support | 1.0% below the last close | turned there twice · 2025-06-06 to 2026-08-10 |
| $6.62 | Resistance | 3.1% above the last close | turned there twice · 2025-07-28 to 2026-09-10 |
| $4.83 | Support | 24.7% below the last close | turned there twice · 2025-09-22 to 2026-01-14 |
| $4.60 | Support | 28.4% below the last close | turned there three times · 2024-10-30 to 2025-11-28 |
| $8.76 | Resistance | 36.4% above the last close | turned there three times · 2026-07-13 to 2026-08-19 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a three-part upward correction — the A-B-C shape chartists use for a pullback — now complete.
This labelling fails — stops being a possible reading at all — if it closes above $10.31.
It is the only labelling that fits these swings, though its proportions are not the textbook ones.
This reading has stood for 39 trading days, since 2026-08-26.
Read from daily closes as of 2026-10-20.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Trading below the 50-day moving average · Pulled back from the 12-month high · Broke down to a new 20-day low · beating the market · Printed a bullish engulfing pair | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low
Based on daily closing prices as of 2026-10-20. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.00 mean, 1=Strong Buy…5=Strong Sell) — 3 analysts
- Mean price target$26.33 range $14.00 – $40.00; median $25.00
Analyst estimates, as of 2026-10-20. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for AGEN
- Consensus EPS estimate$0.04 next reporting period, as of 2026-10-20
- Estimate change, 30 days$0.00 from $0.04, on 2026-09-20, 30-day window
- Readings revised upward0% of 10 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Significant history of net losses and ongoing need for additional capital to complete development and commercialization.","Clinical trials may fail to demonstrate efficacy or identify safety issues, leading to potential regulatory rejection or product withdrawal.","Dependency on achieving market acceptance by physicians and payors in a competitive oncology treatment landscape."]
What changed in the latest 10-Q
AI-assisted comparison of AGEN's 10-Q filed 2026-08-07 against the prior one filed 2026-05-11.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (2026-08-07) adds a section titled 'Strategic Prioritization of Neoadjuvant BOT/BAL in MSS Colon Cancer' describing the ROBBIN Phase 3 trial announced on July 13, 2026 in connection with a Private Placement.
- Newer filing adds that ROBBIN is a planned global randomized Phase 3 trial evaluating neoadjuvant BOT/BAL followed by standard of care versus standard of care alone in previously untreated high-risk Stage II and Stage III MSS colon cancer.
- Newer filing adds that ROBBIN will enroll 850 patients, randomized 1:1, with event free survival (EFS) as primary endpoint.
- Newer filing adds that key elements of the ROBBIN trial design have been informed by FDA feedback.
- Newer filing adds anticipated ROBBIN milestones: first patient dosed in Q1 2027, interim pathologic response data in H2 2027, interim EFS analysis in H2 2029, final EFS analysis in H2 2030.
- Newer filing adds clinical rationale for ROBBIN derived from NEST and UNICORN investigator-sponsored Phase 2 studies of neoadjuvant BOT/BAL in MSS colorectal cancer.
- Newer filing adds that across NEST and UNICORN, BOT/BAL produced pathologic response in approximately 60% to 70% of patients, major pathologic response in approximately 35% to 40%, and pathologic complete response in approximately 30%.
- Newer filing adds a description of BOT as a multifunctional, Fc-enhanced anti-CTLA-4 antibody and BAL as a fully human monoclonal IgG4 anti-PD-1 antibody.
- Newer filing adds that BOT/BAL is investigational and has not been approved by the FDA or authorized for commercial sale in the European Union or any other jurisdiction.
- Newer filing adds that as of June 30, 2026, the approximate fair value of the MiNK investment was $25.5 million.
- Newer filing adds a private placement providing approximately $85.0 million in upfront gross proceeds, before deduction of placement expenses, and up to an additional $255.0 million upon full exercise of accompanying purchase warrants.
- Newer filing adds the discontinuation of the Company's financial support for the CCTG-sponsored BATTMAN Phase 3 study in late-line metastatic MSS colorectal cancer.
- Newer filing adds that the first payment into escrow of $20.0 million (only for use in making payments to Zydus) reflected the total value of the first tranche of clinical supply expected to be delivered by Zydus in 2026.
- Newer filing adds an estimated addressable U.S. annual sales opportunity of more than $7 billion for high-risk Stage II and Stage III MSS colon cancer, with no new curative-intent therapies approved in more than 20 years.
- Newer filing adds that high-risk Stage II and Stage III MSS colon cancer affects an estimated 38,000 patients annually in the United States and more than 200,000 patients worldwide.
- Removed:
- Older filing (2026-05-11) included a trademark statement: 'Agenus, Prophage, Retrocyte Display and STIMULON are trademarks of Agenus Inc. and its subsidiaries. All rights reserved.' which is absent from the newer filing.
- Older filing included a paragraph describing BOT/BAL availability in France under the national Autorisation d'Accès Compassionnel (AAC) framework for eligible patients in MSS metastatic colorectal cancer without active liver metastases, platinum-resistant or platinum-refractory ovarian cancer, and certain advanced soft-tissue sarcomas. This paragraph is absent from the newer filing.
- Older filing included a paragraph describing BAP Pharma as the global distribution partner appointed in April 2026 to support BOT/BAL access programs. This paragraph is absent from the newer filing.
- Older filing included a paragraph describing the commencement of patient enrollment in the global Phase 3 BATTMAN (CCTG CO.33) trial in April 2026, evaluating BOT plus BAL versus best supportive care in approximately 830 patients across more than 100 sites in Canada, France, Australia and New Zealand. This paragraph is absent from the newer filing.
- Older filing included a paragraph describing the January 2026 Zydus collaboration closing, including $91.0 million in cash consideration ($75.0 million for manufacturing facilities and $16.0 million equity investment), exclusive license for India and Sri Lanka, and up to $50.0 million in contingent payments. This paragraph is absent from the newer filing.
- Older filing stated the Company intended during 2026 to seek Accelerated Approval in the United States and Conditional Approval in the European Union for BOT plus BAL in refractory microsatellite-stable metastatic colorectal cancer without active liver metastases. This statement is absent from the newer filing.
- Older filing included a paragraph stating that on May 4, 2026, the SEC informed the Company it concluded its investigation, and on March 24, 2026, the U.S. District Court for the District of Massachusetts granted the motion to dismiss the putative securities class action, with the lead plaintiff filing a Notice of Appeal. This paragraph is absent from the newer filing.
- Older filing stated the approximate fair value of the MiNK investment as $22.9 million as of March 31, 2026; this figure is removed in the newer filing.
- Older filing described BOT/BAL as 'botensilimab (BOT or AGEN1181), alone and in combination with balstilimab (BAL)' and referred to 'BOT plus BAL (BOT/BAL)'; the newer filing replaces this with a different description.
- Reworded:
- Newer filing describes the lead clinical program as 'BOT, a multifunctional, Fc-enhanced anti-CTLA-4 antibody, alone and in combination with BAL, a fully human monoclonal IgG4 anti-PD-1 antibody,' replacing the older description of 'botensilimab (BOT or AGEN1181), alone and in combination with balstilimab (BAL).'
- Newer filing states 'The six months ended June 30, 2026 and the period shortly thereafter included several developments...' whereas the older filing stated 'The first quarter of 2026 and the period shortly thereafter included several developments...'
- Newer filing characterizes the $20.0 million as 'the first payment into escrow of $20.0 million (only for use in making payments to Zydus), reflecting the total value of the first tranche of clinical supply expected to be delivered by Zydus in 2026,' while the older filing described it as 'the first $20.0 million contingent payment was triggered based on contracted work orders for BOT/BAL chemistry, manufacturing and controls (CMC) and production activities.'
- Newer filing states the SEC's investigation conclusion and dismissal of the securities class action as completed developments ('the conclusion of the SEC's investigation as to the Company; the dismissal of the related putative securities class action'), while the older filing described these in a separate paragraph with specific dates and additional details including the lead plaintiff's Notice of Appeal.
- Newer filing describes the strategic collaboration with Zydus in more condensed terms, referencing 'the closing of the strategic collaboration with Zydus Lifesciences Ltd.', while the older filing provided a detailed paragraph on the Zydus collaboration terms.
- Newer filing describes the appointment of 'an exclusive global access distribution partner' in condensed terms, while the older filing provided details about BAP Pharma appointment and AAC program details.
- Newer filing refers to 'continued expansion of physician engagement through regulatory-authorized access pathways' in condensed terms, while the older filing described the France AAC framework and named-patient programs in more detail.
- The older filing's overview text uses 'Our primary business' with slightly different paragraph structure, while the newer filing uses 'Our primary business is immuno-oncology ("I-O"), where we are advancing...' with additional detail on BOT's mechanism of action.
- Notes:
- The newer filing text is truncated at the end ('With median follow-up of approximately 9 to 18 months, all treated p'), so the comparison may not capture all changes present in the full MD&A section.
- The older filing text contains a page number '23' embedded within the BATTMAN description paragraph, suggesting the source text may include formatting artifacts.
- The older filing text is also truncated at 'Botensilimab is a multifunctional ant', so later portions of the older MD&A could not be compared.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales are on record for AGEN — recent Form 4 activity was compensation-related (awards, option exercises, or tax withholding), not open-market buying or selling.
View full insider trading history → View SEC Form 3/4/5 filingsOnly open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding AGEN as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 3,318,895
- Reported value $10,155,817
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 3 increased, 2 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about AGEN's institutional holders → See what each manager we track holds →
Short interest (FINRA)
AGEN had 6,818,562 shares of reported short interest as of the 2026-09-30 FINRA settlement date (delayed, bi-monthly; not real-time).
AGEN had 15.1% of its shares outstanding sold short as of the 2026-09-30 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 5.66 days to cover at the same settlement.
- Reported short interest (shares) 6,818,562
- Short interest (% of shares outstanding) 15.1%
- Prior settlement (shares) 6,803,686
- Reported change 0.22%
- Days to cover (reported) 5.66
Reported to FINRA as of the 2026-09-30 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Bristol Myers Squibb (BMY)
- Merck (MRK)
- AstraZeneca (AZN)
- Roche (RHHBY)
- GSK (GSK)
- Incyte (INCY)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare AGEN vs…
AGENUS INC is found in…
AGEN ranks in…
Frequently asked questions
What does AGENUS INC (AGEN) do?
Agenus is a clinical-stage biotechnology company focused on discovering and developing immuno-oncology therapies for cancer. Its primary pipeline centers on the development of botensilimab (an Fc-enhanced anti-CTLA-4 antibody) and balstilimab (an anti-PD-1 antibody) for the treatment of various cancers, including microsatellite-stable (MSS) colorectal cancer.
What sector is AGENUS INC (AGEN) in?
AGENUS INC (AGEN) is classified in the Health Care sector. Its industry is biotechnology. It trades on NASDAQ.
Who are AGENUS INC's (AGEN) competitors?
Notable peers of AGENUS INC (AGEN) include Bristol Myers Squibb, Merck, AstraZeneca, Roche and GSK. This peer set is informational only — not financial advice.
Is AGENUS INC (AGEN) overbought or oversold right now?
AGENUS INC (AGEN) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 39, in the neutral middle (as of 2026-10-20). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on AGEN come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.